Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (381-390 of 443) with videos related to

Pageof 45
Sort By:
The Lancet. Oncology|December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialMarwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.
JCI Insight|April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patientsVivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.
JCO Precision Oncology|July 9, 2025
Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
JCO Precision Oncology|February 21, 2025
<i>NTRK</i> Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
Pageof 45

Showing results (381-390 of 443) with videos related to

Sort By:
Pageof 45
The Lancet. Oncology|December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialMarwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.
JCI Insight|April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patientsVivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.
JCO Precision Oncology|July 9, 2025
Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
JCO Precision Oncology|February 21, 2025
<i>NTRK</i> Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.
Pageof 45